CERELA   05438
CENTRO DE REFERENCIA PARA LACTOBACILOS
Unidad Ejecutora - UE
artículos
Título:
Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice
Autor/es:
SALVA, SUSANA; MARRANZINO, GABRIELA; VILLENA, JULIO; AGÜERO, GRACIELA; ALVAREZ, SUSANA
Revista:
INTERNATIONAL IMMUNOPHARMACOLOGY
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Amsterdam; Año: 2014 vol. 22 p. 209 - 221
ISSN:
1567-5769
Resumen:
This work evaluated the capacity
of two probiotic strains, Lactobacillus
casei CRL431 and Lactobacillus rhamnosus CRL1506, to
protect against myelosuppression and immunosuppression in cyclophosphamide
(Cy)-treated mice. Changes in mature granulocytes and progenitor cells in bone
marrow (BM) and blood were studied. In addition, the ability of probiotics to
accelerate the recovery of the immune response against the opportunistic
pathogen Candida albicans was
evaluated. Wedemonstrated for the first time that the preventive treatment with
immunomodulatory lactobacilli such as L.
casei CRL431 or L. rhamnosus
CRL1506 was able to increase immature myeloid progenitors in the BM, allowing
an early recovery of myeloid cells after Cy administration. Probiotic
lactobacilli were also capable to induce an early recovery of neutrophils in
blood, improve phagocytic cells recruitment to infectious sites and increase
the resistance against the opportunistic pathogen C. albicans. Although deeper studies regarding the cellular and
molecular mechanisms of probiotic actions are needed, these findings support the
idea that strains like CRL431 and CRL1506 may accelerate the recovery of
Cy-caused immunosuppression by immunopotentiating myeloid cells. Then,
probiotic lactobacilli have the potential to be used as alternatives for lessening
chemotherapy-induced immunosuppression in cancer patients.